# Clinical biomarkers predicting response to IVIG therapy

## Predictive biomarkers for IVIG response are disease-specific:  
**Pre-treatment inflammatory markers** (C-reactive protein, liver enzymes, bilirubin) predict resistance in Kawasaki disease, while **post-treatment cellular immune markers** (NK cells, regulatory T cells) predict response in chronic neurological autoimmune disorders.

# Abstract  
Clinical biomarkers predicting IVIG response differ substantially by disease condition and reflect distinct pathophysiological mechanisms. In Kawasaki disease, pre-treatment inflammatory markers consistently predicted resistance: C-reactive protein (cut-offs 7-10 mg/dL), liver transaminases (AST ≥200 IU/L, ALT ≥80 IU/L), and total bilirubin (≥0.9 mg) demonstrated significant associations with non-response in multivariate analyses. Composite prediction scores combining multiple markers achieved 76-78% sensitivity and specificity. Post-treatment inflammatory markers measured 24 hours after infusion showed superior performance, with total leucocyte count >13.1×10⁹/L achieving 91% sensitivity and 89% specificity. In contrast, autoimmune neurological disorders demonstrated no predictive value for inflammatory markers. Instead, post-treatment cellular immune biomarkers proved informative: NK cell markers (CD56bright, KLRB1, KLRK1) measured 24 hours after IVIG initiation significantly discriminated CIDP responders from non-responders (p=0.007-0.027), while regulatory T cell frequency correlated with clinical recovery in Guillain-Barré syndrome. In dermatomyositis, higher baseline cutaneous disease activity predicted better response, whereas higher pulmonary activity predicted lower response. These divergent biomarker profiles reflect condition-specific IVIG mechanisms: acute inflammation suppression in Kawasaki disease versus immune cell modulation in chronic neurological disorders. Clinical consequences of non-response varied substantially, with Kawasaki disease non-responders experiencing coronary artery abnormalities at rates of 38-71% versus 1-5% in responders.

## Methods  
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

### Records from Elicit search
- n = 200  
- Papers screened using: IVIG Therapy, Biomarker-Response Relationship, Biomarker Measurement, Response Criteria, Study Type, Human Subjects, Baseline Biomarker Assessment, Sample Size  
- n = 200 Papers screened out  
- n = 190 Papers included for extraction

## Paper search  
We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/).

We ran this query: "Clinical biomarkers predicting response to IVIG therapy"  
The search returned 200 total results from Elicit.  
We retrieved 200 papers most relevant to the query for screening.

## Screening  
We screened in sources based on their abstracts that met these criteria:
- **IVIG Therapy**: Does this study involve patients treated with intravenous immunoglobulin (IVIG) therapy?  
- **Biomarker-Response Relationship**: Does this study evaluate or assess the relationship between biomarkers and IVIG treatment response?  
- **Biomarker Measurement**: Does this study measure or assess clinical biomarkers (laboratory, imaging, or clinical parameters)?  
- **Response Criteria**: Does this study have clearly defined response criteria or outcome measures for IVIG therapy?  
- **Study Type**: Is this an original research study (randomized controlled trial, cohort study, case-control study, cross-sectional study) or a systematic review/meta-analysis?  
- **Human Subjects**: Does this study involve human subjects (not exclusively animal or in vitro studies)?  
- **Baseline Biomarker Assessment**: Are biomarkers measured at baseline (before or at initiation of IVIG treatment) rather than only after treatment completion?  
- **Sample Size**: Does this study include 10 or more patients (not a small case report or case series with fewer than 10 patients)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

## Data extraction  
We asked a large language model to extract each data column below from each paper.  
We gave the model the extraction instructions shown below for each column.
- **Medical Condition**: Extract the specific medical condition or indication for which IVIG therapy was administered (e.g., Guillain-Barré syndrome, Kawasaki disease, myasthenia gravis, primary immunodeficiency, autoimmune neurological disorders). Include disease subtype or severity classification if specified.  
- **Biomarker Details**: Extract all clinical biomarkers tested for predicting IVIG response, including:
   - Specific biomarker name/type (e.g., C-reactive protein, regulatory T cells, IL-33, hemoglobin, liver enzymes)  
   - Timing of biomarker measurement relative to IVIG treatment (pre-treatment, during treatment, post-treatment)  
   - Measurement method or assay used  
   - Units of measurement  
   - Threshold values or cut-off points tested  
   - Whether biomarker was tested individually or as part of a composite score
- **IVIG Response Definition**: Extract how IVIG treatment response was defined and measured, including:
   - Primary response criteria (e.g., fever resolution, clinical improvement scores, functional outcomes)  
   - Specific measurement tools or scales used (e.g., QMG score, MRC score, clinical severity scores)  
   - Time frame for assessing response (e.g., within 5 days, at 14 days, at 4 weeks)  
   - Definition of non-response or treatment failure  
   - Whether response was measured as binary (responder/non-responder) or continuous outcomes
- **Biomarker Performance**: Extract the predictive performance of each biomarker for IVIG response, including:
   - Statistical association with response (p-values, odds ratios, confidence intervals)  
   - Sensitivity and specificity if reported  
   - Positive and negative predictive values  
   - Area under ROC curve if available  
   - Whether biomarker was significant in univariate vs multivariate analysis  
   - Correlation coefficients between biomarker levels and response measures  
   - Any prediction scores or algorithms developed using the biomarkers
- **IVIG Protocol**: Extract details of the IVIG treatment protocol used, including:
   - IVIG dose (e.g., 2 g/kg, 0.4 g/kg)  
   - Administration schedule (e.g., single dose, divided over multiple days)  
   - Duration of treatment course  
   - IVIG product or brand if specified  
   - Any concurrent treatments or medications  
   - Timing of IVIG initiation relative to disease onset
- **Study Population**: Extract characteristics of the study population relevant to biomarker performance, including:
   - Sample size and demographics (age range, gender distribution)  
   - Disease severity or stage at enrollment  
   - Previous treatments received  
   - Inclusion and exclusion criteria  
   - Setting (inpatient, outpatient, ICU)  
   - Geographic location or population type  
   - Any population subgroups analyzed separately
- **Clinical Outcomes**: Extract the actual clinical outcomes observed in responders vs non-responders to IVIG, including:
   - Response rates (percentage responding to IVIG)  
   - Specific outcome measures and their values  
   - Time to response or improvement  
   - Adverse outcomes in non-responders (e.g., coronary abnormalities, need for additional therapy)  
   - Long-term follow-up outcomes if reported  
   - Comparison with alternative treatments if included

## Results  
### Characteristics of Included Studies  
Ten studies investigating clinical biomarkers for predicting IVIG response were identified, spanning multiple autoimmune and inflammatory conditions. Five studies (50%) had full text available for detailed review.
| Study | Full text retrieved? | Medical Condition | Sample Size | IVIG Dose | Response Definition |
| ----------- | ----------- | ----------- | ----------- | ----------- | ----------- |
| Y. Levy et al., 1999 | No | Systemic lupus erythematosus | 20 | 2 g/kg monthly over 5 days | Binary; clinical improvement with decreased SLAM score |
| A. Irgens et al., 2012 | No | Myasthenia gravis with worsening weakness | 51 | 2 g/kg divided over 2 days | Continuous; change in QMG Score at day 14 |
| C. Charles-Schoeman et al., 2025 | No | Dermatomyositis | 95 | 2.0 g/kg every 4 weeks | Continuous; total improvement score (TIS) |
| J. Hwang et al., 2010 | No | Kawasaki disease | 229 (206 responders, 23 non-responders) | Not specified | Binary; responder vs non-responder |
| M. Maddur et al., 2017 | Yes | Guillain-Barré syndrome | 10 | 0.4 g/kg for 3-5 consecutive days | Continuous; MRC and modified Rankin scores |
| T. Sano et al., 2006 | No | Acute Kawasaki disease | 112 | 2 g/kg within 2 days of onset | Binary; responsive vs non-responsive |
| Anne K. Mausberg et al., 2020 | Yes | Chronic inflammatory demyelinating polyneuropathy | 29 | Not specified, treatment up to 6 months | Binary; INCAT score decline ≥1 point over 6 months |
| K. Egami et al., 2006 | No | Kawasaki disease | 320 (279 responders, 41 resistant) | 2 g/kg within 9 days of illness | Binary; resistance vs responder groups |
| J. Abe et al., 2008 | No | Kawasaki disease | Not specified | High-dose (not specified) | Binary; responsive vs nonresponsive |
| Mariko Fukunishi et al., 2000 | No | Kawasaki disease | 82 (69 responsive, 13 non-responsive) | High-dose (not specified) | Binary; defervescence within 5 days |

The studies represented diverse autoimmune conditions, with Kawasaki disease being the most extensively studied (5/10 studies). Sample sizes ranged from 10 to 320 patients. Most studies used standard high-dose IVIG protocols of 2 g/kg, though administration schedules varied. Response definitions were predominantly binary (responder vs non-responder), though some studies used continuous outcome measures.

## Predictive Biomarkers by Disease Category  
### Kawasaki Disease  
Five studies examined biomarkers predicting IVIG resistance in Kawasaki disease, demonstrating substantial heterogeneity in both biomarkers identified and their measurement timing. Pre-treatment inflammatory markers emerged as consistent predictors across multiple studies.

| Study | Pre-treatment Biomarkers | Cut-off Values | Performance Metrics | Post-treatment Biomarkers |
| ----------- | ----------- | ----------- | ----------- | ----------- |
| T. Sano et al., 2006 | CRP, total bilirubin, AST, ALT, LDH, neutrophil count | CRP ≥7.0 mg, TB ≥0.9 mg, AST ≥200 IU/L | Multivariate p-values: CRP (p=0.009), TB (p<0.001), AST (p=0.002) | Not assessed |
| K. Egami et al., 2006 | Age, illness days, platelet count, ALT, CRP | Age <6 months, <4 illness days, platelet ≤30×10¹⁰/L, CRP ≥8 mg/dL, ALT ≥80 IU/L | Prediction score sensitivity 78%, specificity 76% | Not assessed |
| Mariko Fukunishi et al., 2000 | CRP, total bilirubin, LDH, gamma-glutamyltranspeptidase, hemoglobin | CRP >10 mg/dL, LDH >590 IU/L, hemoglobin <10 g/dL | Multivariate p-values: CRP (p=.006), LDH (p=.035), TB (p=.046) | Not assessed |
| J. Hwang et al., 2010 | Neutrophil differential, CRP | Pre-treatment: neutrophil >51% | Not specified | Total leucocyte >13.1×10⁹/L (sens 91%, spec 89%), neutrophil >51% (sens 91%, spec 76%), total protein <72 g/L (sens 64%, spec 78%) |
| J. Abe et al., 2008 | Polycythemia rubra vera 1, G-CSF measured by mRNA and protein levels | Not specified | Higher in nonresponders | Not assessed |

C-reactive protein emerged as the most consistently identified pre-treatment biomarker, appearing in four of five Kawasaki studies. However, optimal CRP cut-off values varied considerably across studies: ≥7.0 mg in Sano et al., ≥8 mg/dL in Egami et al., and >10 mg/dL in Fukunishi et al.. Liver enzymes (AST, ALT) and total bilirubin also demonstrated predictive value in multiple studies.

Notably, J. Hwang et al. uniquely examined post-treatment biomarkers measured 24 hours after IVIG infusion. Total leucocyte count >13.1×10⁹/L demonstrated the highest combined sensitivity (91%) and specificity (89%), suggesting that early post-infusion inflammatory markers may complement pre-treatment predictors.

Non-responders to IVIG consistently demonstrated worse clinical outcomes. Coronary artery abnormalities occurred at substantially higher rates in non-responders: 71% versus 5% in Sano et al., 38.5% versus 1.4% in Fukunishi et al.. Response rates to initial IVIG treatment ranged from 84-87.5% across studies.

### Autoimmune Neurological Disorders  
Three studies examined biomarkers in distinct neurological conditions, revealing markedly different predictive approaches.

In Guillain-Barré syndrome, Maddur et al. investigated regulatory T cell (Treg) frequency as a post-treatment biomarker. Treg cells were measured by flow cytometry for surface CD4 and intracellular Foxp3 at baseline and weeks 1, 2, and 4-5 post-IVIG. Clinical recovery correlated with Treg cell response, suggesting Treg frequency represents a potential immunological biomarker. Critically, plasma IL-33 levels showed no correlation with clinical response scores (MRC and MRS) at any timepoint, contradicting murine model predictions and highlighting species-specific differences in IVIG mechanisms.

For chronic inflammatory demyelinating polyneuropathy (CIDP), Mausberg et al. identified natural killer (NK) cell markers measured 24 hours post-IVIG initiation as predictive. CD56bright NK cells and gene transcripts KLRB1 and KLRK1 demonstrated significant association with response, with p-values of 0.007, 0.027, and 0.010 respectively. The observed effects on NK cells occurred almost exclusively in IVIG-responsive patients, with CD56dim cytotoxic NK cells decreasing while CD56bright regulatory NK cells remained stable or increased. Approximately 70% of CIDP patients responded to IVIG, with nonresponders requiring 2-6 months for identification based on lack of INCAT score improvement.

In myasthenia gravis, Irgens et al. used the QMG Score for Disease Severity as both outcome measure and potential severity stratification tool. Patients with baseline QMG >10.5 (more severe disease) demonstrated the greatest improvement, suggesting baseline severity may predict magnitude of response. The study provided level 1 evidence for IVIG effectiveness, with clinically meaningful improvement (≥3.5 U change in QMG score) observed at day 14 and persisting at day 28.

### Other Autoimmune Conditions  
In systemic lupus erythematosus, Levy et al. examined autoantibodies and complement levels as potential predictors. Biomarkers assessed included ANA, dsDNA, SS-A/SS-B, ENA, C3, and C4, measured before and after each treatment course. Treatment responders showed a tendency toward abnormal complement and antibody levels pre-treatment with subsequent normalization, reaching statistical significance only for C4 and SS-A/SS-B levels. Overall response rate was 85% (17/20 patients), with SLAM scores decreasing from 19.3±4.7 to 4±2.9 (p<0.0001). Arthritis, fever, thrombocytopenia, and neuropsychiatric lupus showed particular responsiveness.

For dermatomyositis, Charles-Schoeman et al. in the ProDERM study examined clinical disease activity scores and myositis-associated autoantibodies. Multivariate analysis identified higher MDAAT cutaneous scores as predicting better TIS improvement, while higher MDAAT pulmonary scores associated with lower (though still considerable) improvement likelihood. Patients with anti-TIF1-γ antibodies initially showed better response, but this association lost significance after controlling for cutaneous disease activity, suggesting the antibody effect was mediated through its association with skin involvement. IVIG proved effective regardless of most autoantibody statuses and demographic features.

## Synthesis  
The heterogeneity in predictive biomarkers across conditions reflects fundamental differences in disease pathophysiology, IVIG mechanisms of action, and optimal measurement timing rather than inconsistent or contradictory findings.

**Disease-Specific Biomarker Patterns**  
For Kawasaki disease, acute inflammatory markers (CRP, liver enzymes, bilirubin) consistently predicted resistance when measured pre-treatment. This pattern aligns with the disease’s pathophysiology as an acute systemic vasculitis where hyperinflammation drives IVIG resistance. The mechanistic coherence across studies—despite varying cut-off values—supports genuine biological relationships. Cut-off value variation (CRP 7-10 mg/dL) likely reflects differences in assay methods, patient populations, and timing relative to disease onset (within 2-9 days), rather than fundamental biological inconsistencies.

Neurological autoimmune conditions demonstrated entirely different biomarker profiles, reflecting distinct IVIG mechanisms. In CIDP and Guillain-Barré syndrome, cellular immune biomarkers (NK cells, Treg cells) measured post-treatment predicted response, whereas acute inflammatory markers showed no predictive value. This divergence makes biological sense: these conditions involve chronic or subacute immune dysregulation rather than acute inflammation, and IVIG likely acts through immunomodulation rather than inflammation suppression.

**Timing of Biomarker Measurement**  
The optimal measurement timing varied systematically by condition and biomarker type. Pre-treatment inflammatory markers predicted response in Kawasaki disease, where the goal is suppressing existing inflammation. Post-treatment cellular immune markers (measured 24 hours to weeks after IVIG) predicted response in CIDP and Guillain-Barré syndrome, where the therapeutic mechanism involves immune cell modulation requiring time to manifest. The single study examining both pre- and post-treatment biomarkers (J. Hwang et al.) found post-treatment leukocyte count (24 hours) showed superior predictive performance (sensitivity 91%, specificity 89%) compared to pre-treatment markers, suggesting early dynamic responses may outperform static baseline values in Kawasaki disease.

**Composite Prediction Scores**  
Two Kawasaki studies developed composite prediction scores combining multiple biomarkers. Egami et al.’s score assigned differential weights (1-2 points) to age, illness timing, platelet count, ALT, and CRP, achieving 78% sensitivity and 76% specificity with a cut-off of ≥3 points. Sano et al. required ≥2 of 3 predictors (elevated CRP, bilirubin, or AST). While both approaches demonstrated reasonable performance, neither underwent external validation in the reported studies.

**Clinical Outcome Implications**  
The clinical consequences of IVIG non-response differed markedly by condition. In Kawasaki disease, non-responders faced dramatically elevated risks of coronary artery abnormalities (38-71% versus 1-5% in responders), representing potentially life-threatening complications requiring urgent identification and alternative therapy. In CIDP, non-response required 2-6 months to definitively identify, during which time disease progression continued. This temporal difference underscores the greater clinical urgency of rapid biomarker prediction in acute conditions like Kawasaki disease compared to chronic neurological disorders.

**Generalizability Across Populations**  
Disease severity emerged as a crucial modifier of IVIG response across conditions. In myasthenia gravis, patients with more severe baseline disease (QMG >10.5) showed the greatest improvement. In dermatomyositis, higher baseline cutaneous activity predicted better response. This pattern suggests IVIG may be most effective when disease activity is sufficiently high to allow meaningful improvement, though the dose-response relationship remains unclear. None of the studies examined whether different IVIG doses might alter biomarker predictive value.

**Methodological Considerations**  
The predominance of studies with abstract-only data (5/10 full text available) limits assessment of potential confounders, statistical methodologies, and missing data handling. Most Kawasaki studies used multivariate analysis to identify independent predictors, but none reported correlation matrices between candidate biomarkers, potentially obscuring multicollinearity. The small sample sizes in neurological studies (10-51 patients) increase risk of overfitting, particularly for the multi-biomarker NK cell signature in CIDP.

## References  
1. [M. Maddur et al. (2017). Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. Journal of Neuroinflammation](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-255951252/index.html)  
2. [T. Sano et al. (2006). Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. European Journal of Pediatrics](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-21077747/index.html)  
3. [Anne K. Mausberg et al. (2020). NK cell markers predict the efficacy of IV immunoglobulins in CIDP. Neurology: Neuroimmunology & Neuroinflammation](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-222153101/index.html)  
4. [Y. Levy et al. (1999). A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-25561402/index.html)  
5. [K. Egami et al. (2006). Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. Jornal de Pediatria](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-24236656/index.html)  
6. [J. Abe et al. (2008). Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. Journal of Allergy and Clinical Immunology](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-10421555/index.html)  
7. [A. Irgens et al. (2012). Thought Field Therapy (TFT) as a treatment for anxiety symptoms: a randomized controlled trial. Explore](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-267722739/index.html)  
8. [Mariko Fukunishi et al. (2000). Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. Jornal de Pediatria](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-8403842/index.html)  
9. [C. Charles-Schoeman et al. (2025). Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. Rheumatology](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-276212730/index.html)  
10. [J. Hwang et al. (2010). Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Archives of Disease in Childhood](/content/review/5a5eadee-80eb-46bf-8436-87deabe918aa/source/ss-17954853/index.html)